Level 34, 50 Bridge Street
New South Wales
About Recce Pharma
Recce Ltd is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.
Founder: Graham JH Melrose
CFO: Peter Williams
47 articles with Recce Pharma
Recce Pharmaceuticals Ltd is pleased to announce the Chinese Patent Office has granted Patent Family 3 “ Anti-Virus Agent and Method for Treatment Of Viral Infections ”
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria
RECCE is pleased to announce positive efficacy of RECCE® 327 (R327) against Clostridium perfringens (C. perfringens) and Streptococcus pyogenes (S. pyogenes), two main strains of bacteria associated with necrotizing fasciitis, also known as ‘flesh-eating’ disease – a life-threatening bacterial infection with a mortality rate of up to 80%.
Recce Pharmaceuticals Ltd has accepted an invitation to present at the World Microbe Forum following confirmation to publish a recent abstract in the 2021 program.
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Progresses to Stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO
Further study completed at the Doherty Institute as part of SARS-CoV-2 Antiviral Screening Program calculates IC50 of RECCE® 327 (R327) to be 2,046 PPM and the CC50 for R327 to be 5108 PPM
Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens
More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE® 327 (R327) in independent bacterial efficacy studies
Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives is pleased to announce the Company’s shares are now Dual Listed on the Frankfurt Stock Exchange
Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives is pleased to announce it has commenced the application process to dual list its stock on the Frankfurt Stock Exhange.
Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds
Highlights: Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious disease on chronic burn wounds in up to 30 patients
From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
Highlights: RECCE ® 327 and RECCE ® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a well-accepted model of infection Intranasal administration of both compounds supports multiple potential modes of administration against SARS-CoV-2 Company committed to its COVID-19 activities as part of its infectious disease portfolio
Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its clinical programs. Topical Phase I/II Human Clinical Trial Submission Topical Phase I/II human clinical study is on track and progressing well. The Company recently announced it has received Human Research Ethics Approval for its Phase I/II human topical clinical trial in infected burn wounds an
Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled “Anti-virus Agent and Method for Treatment of Viral Infection” , furthering marketing and manufacturing monopolies to February 2037. “Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Study Evaluating Topical Spray-On Synthetic Antibiotic RECCE® 327 on Chronic Burn Wounds
Highlights : Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two week period Study anticipated to be sponsored by South Metropolitan Health Service , Department of Health, Government of Western Australia (WA) Fiona Stanley Hospital ( B urns U nit) in Perth Western Australia identified as study site SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE)
Recce Pharmaceuticals and Murdoch Children’s Research Institute to Evaluate RECCE® 435 Against Helicobacter pylori Stomach Bacteria
Highlights : Murdoch Children’s Research Institute to evaluate the in-vivo antimicrobial activity of RECCE ® 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies program Studies led by H. pylori infectious disease expert Professor Philip Sutton Multiple world-first data opportunities over 12 months study program – anticipated human clinical trial beyond SYDNEY, Australia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Recce Pharma
9/4/2020Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
9/3/2020Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
Recce Pharmaceuticals Announces Positive Oral Data on New RECCE® 435 Against Helicobacter Pylori in Animal Model
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced positive efficacy activity against Helicobacter pylori bacteria in rats treated with new antibiotic RECCE® 435, including a favorable toxicity profile in a related study.
Recce Pharmaceuticals to Give Opening R&D Address at 2020 Virtual World Antibiotic Resistance Congress
Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Company ), the Company developing New Classes of Synthetic Anti-infectives, today announced that it will be delivering the Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress from the 8th – 9th October 2020. Due to the global pandemic, the conference will be held entirely virtually. The two-day World AMR Congress is the largest commercially focused conference with AMR at i
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE® Compounds in Expanded SARS-CoV-2 Program
Highlights: International study will be conducted in a laboratory at a leading academic institution in the U.S. to evaluate anti-viral activity of RECCE ® 327 and new antiviral formulation RECCE ® 529 Expanded program utilizing Centers for Disease Control (CDC) SARS-CoV-2 clinical isolate SARS-Related Coronavirus 2, Isolate USA-WA1/2020 Preliminary data anticipated September 2020 SYDNEY, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Compa